Boston Scientific, Medtronic, Abbott and J&J unveiled new data for their PFA devices in tandem with the Heart Rhythm ...

Researchers sought to determine 1-year outcomes in patients being treated with tirzepatide who have atrial fibrillation.

Abbott has reported new data from its prospective, non-randomised Volt CE Mark Study, indicating that individuals treated ...

“It was an experience that dramatically improved my life,” said Mike Prescott of Kenosha, who retired a couple of years ago ...

When it comes to a simple, accessible, beneficial form of exercise, walking is hard to top – and a new study suggests that ...

The benefit of GLP-1 therapy couldn’t be explained by weight loss, suggesting that some pleiotropic effects may be at work.

Emerging pulsed field ablation systems had their moments in the spotlight at the annual meeting of the Heart Rhythm Society ...

A system hybridizing cardiac contractility modulation and implantable cardioverter defibrillation successfully converted ...

SGLT2 inhibitors, compared with GLP1 agonists, significantly lower risk for atrial fibrillation in patients with type 2 diabetes.

GLP-1 use significantly lowered risk for atrial fibrillation-related events for patients with diabetes, AF and obesity, with ...

Patients with a high probability of HFpEF may experience greater benefits from atrial fibrillation ablation than those with a ...